Moises Labrador-Horrillo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8723293/publications.pdf

Version: 2024-02-01

96 papers

3,279 citations

172207 29 h-index 54 g-index

103 all docs

103
docs citations

103 times ranked 4202 citing authors

#	Article	IF	CITATIONS
1	Usefulness of antiâ€p155 autoantibody for diagnosing cancerâ€associated dermatomyositis: A systematic review and metaâ€analysis. Arthritis and Rheumatism, 2012, 64, 523-532.	6.7	286
2	Microbiome and Allergic Diseases. Frontiers in Immunology, 2018, 9, 1584.	2.2	211
3	Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. New England Journal of Medicine, 2017, 376, 1131-1140.	13.9	169
4	Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	145
5	Usefulness and Limitations of Sequential Serum Tryptase for the Diagnosis of Anaphylaxis in 102 Patients. International Archives of Allergy and Immunology, 2013, 160, 192-199.	0.9	144
6	Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus, 2005, 14, 534-542.	0.8	124
7	Plasma contact system activation drives anaphylaxis in severe mast cell–mediated allergic reactions. Journal of Allergy and Clinical Immunology, 2015, 135, 1031-1043.e6.	1.5	120
8	Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Review of Clinical Immunology, 2018, 14, 215-224.	1.3	112
9	Myositis-specific and myositis-associated antibodies in a series of eighty-eight mediterranean patients with idiopathic inflammatory myopathy. Arthritis and Rheumatism, 2006, 55, 791-798.	6.7	107
10	Coâ€factorâ€enhanced food allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1316-1318.	2.7	104
11	Malignancy and myositis: novel autoantibodies and new insights. Current Opinion in Rheumatology, 2010, 22, 627-632.	2.0	89
12	Antihistone and anti–double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus. American Journal of Medicine, 2004, 116, 165-173.	0.6	83
13	Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis. Rheumatology, 2018, 57, 388-396.	0.9	81
14	Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus, 2003, 12, 287-296.	0.8	79
15	Extended immunophenotyping reference values in a healthy pediatric population. Cytometry Part B - Clinical Cytometry, 2019, 96, 223-233.	0.7	79
16	Familial CD8 deficiency due to a mutation in the CD8 \hat{l} ± gene. Journal of Clinical Investigation, 2001, 108, 117-123.	3.9	76
17	Cancer-Associated Myositis and Anti-p155 Autoantibody in a Series of 85 Patients With Idiopathic Inflammatory Myopathy. Medicine (United States), 2010, 89, 47-52.	0.4	75
18	Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. Expert Opinion on Biological Therapy, 2013, 13, 1225-1228.	1.4	62

#	Article	IF	Citations
19	The Mast Cell, Contact, and Coagulation System Connection in Anaphylaxis. Frontiers in Immunology, 2017, 8, 846.	2.2	60
20	Nailfold Capillary Microscopy in Adults with Inflammatory Myopathy. Seminars in Arthritis and Rheumatism, 2010, 39, 398-404.	1.6	58
21	Allergic diseases in the elderly. Clinical and Translational Allergy, 2011, 1, 11.	1.4	57
22	Anti-TIF1 \hat{I}^3 antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Annals of the Rheumatic Diseases, 2012, 71, 993-996.	0.5	48
23	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Advances, 2022, 6, 774-784.	2.5	42
24	Immunotherapy in allergic rhinitis and lower airway outcomes. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 35-42.	2.7	40
25	Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. Medicina ClÃnica, 2022, 159, 116-123.	0.3	40
26	Involvement of Can f 5 in a Case of Human Seminal Plasma Allergy. International Archives of Allergy and Immunology, 2012, 159, 143-146.	0.9	33
27	Antihistamineâ€resistant chronic spontaneous urticaria remains undertreated: 2â€year data from the AWARE study. Clinical and Experimental Allergy, 2020, 50, 1166-1175.	1.4	33
28	Muscle inflammation, autoimmune Addison's disease and sarcoidosis in a patient with dysferlin deficiency. Neuromuscular Disorders, 2006, 16, 208-209.	0.3	31
29	Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1599-1609.e1.	2.0	31
30	Identification of a novel myositis-associated antibody directed against cortactin. Autoimmunity Reviews, 2014, 13, 1008-1012.	2.5	30
31	Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organization Journal, 2018, 11, 32.	1.6	30
32	Management of urticaria: not too complicated, not too simple. Clinical and Experimental Allergy, 2015, 45, 731-743.	1.4	28
33	Anti-MDA5 dermatomyositis and progressive interstitial pneumonia. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 49-50.	0.2	27
34	Activation of the signal transducer and activator of transcription-1 in diffuse proliferative lupus nephritis. Lupus, 2007, 16, 483-488.	0.8	24
35	Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Design, Development and Therapy, 2015, 9, 4909.	2.0	24
36	Statin-associated autoimmune myopathy: A distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories. Autoimmunity Reviews, 2016, 15, 1161-1166.	2.5	24

#	Article	IF	Citations
37	Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e245-e246.	1.3	23
38	Therapeutic Strategy According to Differences in Response to Omalizumab in Patients With Chronic Spontaneous Urticaria. Journal of Investigational Allergology and Clinical Immunology, 2019, 29, 338-348.	0.6	21
39	Induction of cell death by sera from patients with acute brain injury as a mechanism of production of autoantibodies. Arthritis and Rheumatism, 2002, 46, 3290-3300.	6.7	19
40	Ageâ€specific pediatric reference ranges for immunoglobulins and complement proteins on the Optilite ^{â,,¢} automated turbidimetric analyzer. Journal of Clinical Laboratory Analysis, 2018, 32, e22420.	0.9	19
41	Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy. Rheumatology, 2009, 48, 676-679.	0.9	18
42	Anti-ganglioside antibodies in patients with systemic lupus erythematosus and neurological manifestations. Lupus, 2012, 21, 611-615.	0.8	18
43	DNASE Imutation and systemic lupus erythematosus in a Spanish population: Comment on the article by Tew et al. Arthritis and Rheumatism, 2002, 46, 1974-1976.	6.7	16
44	Omalizumab for the treatment of chronic inducible urticaria in 80 patients. British Journal of Dermatology, 2021, 184, 167-168.	1.4	16
45	Multiplex family?based study in systemic lupus erythematosus: association between the R620W polymorphism of PTPN22 and the Fc?Rlla (CD32A) R131 allele. Tissue Antigens, 2006, 68, 432-438.	1.0	15
46	A Comparative Study of Sex Distribution, Autoimmunity, Blood, and Inflammatory Parameters in Chronic Spontaneous Urticaria with Angioedema and Chronic Histaminergic Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2284-2292.	2.0	15
47	Inflammatory myopathy: diagnosis and clinical course, specific clinical scenarios and new complementary tools. Expert Review of Clinical Immunology, 2015, 11, 737-747.	1.3	14
48	Vertebrate Tropomyosin as an Allergen. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 51-53.	0.6	14
49	One-Dilution Rapid Desensitization Protocol toÂChemotherapeutic and Biological Agents: AÂFive-Year Experience. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4045-4054.	2.0	14
50	The neural network as a predictor of cancer in patients with inflammatory myopathies. Arthritis and Rheumatism, 2002, 46, 2547-2548.	6.7	13
51	IMMEDIATE-TYPE HYPERSENSITIVITY REACTION TO LEVOTHYROXINE AND DESENSITIZATION. Annals of Allergy, Asthma and Immunology, 2008, 100, 513-514.	0.5	13
52	Mixed Connective Tissue Disease and Epitope Spreading. Journal of Clinical Rheumatology, 2017, 23, 155-159.	0.5	13
53	Spirometric Maneuvers and Inhaled Salbutamol Do Not Affect Exhaled Nitric Oxide Measurements among Patients with Allergic Asthma. Respiration, 2012, 83, 239-244.	1.2	11
54	Identification of thaumatinâ€like protein and aspartyl protease as new major allergens in lettuce (<i><scp>L</scp>actuca sativa</i>). Molecular Nutrition and Food Research, 2013, 57, 2245-2252.	1.5	11

#	Article	IF	Citations
55	Omalizumab: what benefits should we expect?. European Journal of Dermatology, 2016, 26, 340-344.	0.3	11
56	Management of chronic spontaneous urticaria in routine clinical practice: A Delphi-method questionnaire among specialists to test agreement with current European guidelines statements. Allergologia Et Immunopathologia, 2017, 45, 134-144.	1.0	10
57	Severe anaphylaxis due to crocodile-meat allergy exhibiting wide cross-reactivity with fish allergens. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 669-670.e1.	2.0	10
58	More on Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib. New England Journal of Medicine, 2015, 372, 1273-1274.	13.9	9
59	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. PLoS ONE, 2020, 15, e0244627.	1.1	9
60	Component-Resolved Diagnosis of Dog Allergy. Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 185-187.	0.6	9
61	Antibodies against a novel nucleolar and cytoplasmic antigen (p105-p42) present in the sera of patients with a subset of rheumatoid arthritis (RA) with signs of scleroderma. Clinical and Experimental Immunology, 1998, 114, 301-310.	1.1	7
62	Molecular diagnosis usefulness for idiopathic anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 248-252.	1.1	7
63	Successful Adaptation of Bee Venom Immunotherapy in a Patient Monosensitized to Api m 10. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 296-298.	0.6	7
64	Guidelines on the clinical usefulness of determination of specific immunoglobulin E to foods. Journal of Investigational Allergology and Clinical Immunology, 2009, 19, 423-32.	0.6	7
65	Generalised delayed desquamative exanthema after intradermal testing with betalactam antibiotics. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 702-703.	2.7	6
66	Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study). Health and Quality of Life Outcomes, 2019, 17, 23.	1.0	6
67	Digital technology for anaphylaxis management impact on patient behaviour: A randomized clinical trial. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1507-1516.	2.7	6
68	Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study. Clinical and Experimental Rheumatology, 2020, 38, 67-73.	0.4	6
69	Relevance of Allergenic Sensitization to Cynodon dactylon and Phragmites communis: Cross-reactivity With Pooideae Grasses. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 295-303.	0.6	5
70	Anaphylaxis Induced by Conlinin, a 2S Storage Protein in Flaxseed. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 56-58.	0.6	5
71	Delayed drug hypersensitivity to bortezomib: Desensitization and tolerance to its analogue carfilzomib. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1384-1386.	2.7	5
72	Case 26-2001: Scleroderma Renal Crisis and Polymyositis. New England Journal of Medicine, 2002, 346, 1916-1918.	13.9	4

#	Article	IF	CITATIONS
73	Anaphylactic shock to meropenem with ertapenem tolerance: A case report. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2057-2058.	2.0	4
74	Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy. Current Rheumatology Reviews, 2005, 1, 157-165.	0.4	3
75	Enfermedad de riesgo vital de origen respiratorio o alérgico en el deporte. Apunts Medicine De L'Esport, 2015, 50, 35-42.	0.5	3
76	Cancer-associated Dermatomyositis: Does the PD-1 Checkpoint Pathway Play a Role?. Journal of Rheumatology, 2018, 45, 731-732.	1.0	3
77	The role of BALB/c donor CD8+ lymphocytes in graft-versus-host disease in (BALB/c x A/J)F1 (CAF1) mice. Journal of Immunology, 1996, 156, 997-1005.	0.4	3
78	A Newborn with Erythematous, Desquamative Plaques. Pediatric Dermatology, 2008, 25, 97-98.	0.5	2
79	Results of the oral egg-challenge test performed on two different groups of children. One group with a history, suggestive of allergic reaction with egg intake and the other group sensitised to hen's egg without previous egg intake. Allergologia Et Immunopathologia, 2010, 38, 233-240.	1.0	2
80	Kounis Syndrome. Current Treatment Options in Allergy, 2019, 6, 289-296.	0.9	2
81	Quantitative measurement of allergen-specific immunoglobulin E levels in mass units (ng/mL): an interlaboratory comparison. Journal of Investigational Allergology and Clinical Immunology, 2012, 22, 387-9.	0.6	2
82	First Clinical Trial with a Medical Device for Anaphylaxis Management. Journal of Allergy and Clinical Immunology, 2018, 141, AB149.	1.5	1
83	Fatal Anaphylactic Shock Induced by Intravenous Gelatin Colloid: A Postmortem Allergological Work-up. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 143-145.	0.6	1
84	VALIDA project: Validation of allergy <i>in vitro </i> diagnostics assays (Tools and recommendations) Tj ETQq0 0 Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0 rgBT /O\ 0.1	verlock 10 Tf ! 1
85	Management of asthma in the emergency department: a consensus statement. Emergencias, 2018, 30, 268-277.	0.6	1
86	Milk and cow's meat allergy in a child: A clinical case. Revista Portuguesa De Imunoalergologia, 2021, 29, .	0.1	1
87	Exposing and Overcoming Limitations of Clinical Laboratory Tests in COVID-19 by Adding Immunological Parameters; A Retrospective Cohort Analysis and Pilot Study. Frontiers in Immunology, 0, 13, .	2.2	1
88	Host H-2 haplotype modulates the induction of host-versus-graft disease after the induction of neonatal tolerance to H-2 alloantigens International Journal of Molecular Medicine, 1998, 1, 431-7.	1.8	0
89	Use of an artificial neural network to predict cancer development in patients with inflammatory myopathy: Comment on the letter by Selva O'Callaghan et al. Arthritis and Rheumatism, 2003, 48, 1168-1169.	6.7	0
90	Specific molecular allergic sensitisation patterns in pediatric polysensitised patients. World Allergy Organization Journal, 2015, 8, A152.	1.6	0

#	Article	IF	CITATIONS
91	MiopatÃas inflamatorias. Medicine, 2017, 12, 1679-1689.	0.0	O
92	Histaminergic angioedema: similarities and differences between isolated angioedema and chronic urticaria with angioedema. Journal of Allergy and Clinical Immunology, 2020, 145, AB200.	1.5	O
93	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. , 2020, 15, e0244627.		O
94	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. , 2020, 15, e0244627.		0
95	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. , 2020, 15, e0244627.		O
96	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis., 2020, 15, e0244627.		0